Skip to main content
Egyptian Liver Journal

Table 3 VEGF through the study period

From: Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals

HCV group

VEGF1

VEGF2

VEGF3

Values (median (Q1–Q3))

173.4 (146.6–199.3)

42.2 (31.3–78.3)

44.1 (31.8–55.3)

P value

< 0.001

Post hoc

 

 VEGF1–VEGF2

< 0.001

 VEGF1–VEGF3

< 0.001

 VEGF2–VEGF3

0.09

  1. VEGF1 measured at the end of treatment, VEGF2 measured one month after the end of treatment, and VEGF3 measured 3 months after the end of treatment
Back to article page